FDA Orange Book
Generic for Liquaemin Sodium
Liquaemin Sodium contains heparin. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Liquaemin Sodium is heparin. 9 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AP. Generics match 4 of the 5 Liquaemin Sodium products the Orange Book lists.
Run it in Rivvi
Map Liquaemin Sodium and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Liquaemin Sodium products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| injectable, injection | 1,000 UNITS/ML | Discontinued | None | 11 | AP |
| injectable, injection | 10,000 UNITS/ML | Discontinued | None | 9 | AP |
| injectable, injection | 20,000 UNITS/ML | Discontinued | None | 3 | AP |
| injectable, injection | 40,000 UNITS/ML | Discontinued | None | 0 | None |
| injectable, injection | 5,000 UNITS/ML | Discontinued | None | 11 | AP |
NDA 000552, held by ASPEN GLOBAL INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic heparin
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| HOSPIRA INC | 088100 | None (No TE code listed) | April 28, 1983 | 5,000 UNITS/ML |
| HOSPIRA INC | 089522 | AP (A-rated, therapeutically equivalent) | May 4, 1987 | 10,000 UNITS/ML |
| HOSPIRA INC | 090571 | AP (A-rated, therapeutically equivalent) | August 31, 2009 | 1,000 UNITS/ML, 10,000 UNITS/ML, 5,000 UNITS/ML |
| SAGENT PHARMACEUTICALS INC | 090808 | AP (A-rated, therapeutically equivalent) | June 30, 2010 | 1,000 UNITS/ML, 10,000 UNITS/ML, 5,000 UNITS/ML |
| SAGENT PHARMACEUTICALS INC | 090810 | AP (A-rated, therapeutically equivalent) | June 30, 2010 | 1,000 UNITS/ML |
| SAGENT PHARMACEUTICALS INC | 090809 | AP (A-rated, therapeutically equivalent) | June 30, 2010 | 20,000 UNITS/ML |
| PLANO PHARMACEUTICALS INC | 091682 | AP (A-rated, therapeutically equivalent) | June 8, 2011 | 1,000 UNITS/ML, 5,000 UNITS/ML |
| PLANO PHARMACEUTICALS INC | 201002 | AP (A-rated, therapeutically equivalent) | June 8, 2011 | 10,000 UNITS/ML |
| SHENZHEN TECHDOW PHARMACEUTICAL CO LTD | 202957 | AP (A-rated, therapeutically equivalent) | June 12, 2014 | 1,000 UNITS/ML, 5,000 UNITS/ML |
| SHENZHEN TECHDOW PHARMACEUTICAL CO LTD | 202732 | AP (A-rated, therapeutically equivalent) | June 12, 2014 | 1,000 UNITS/ML |
| SHENZHEN TECHDOW PHARMACEUTICAL CO LTD | 203198 | AP (A-rated, therapeutically equivalent) | June 12, 2014 | 10,000 UNITS/ML, 20,000 UNITS/ML |
| SHENZHEN TECHDOW PHARMACEUTICAL CO LTD | 202733 | AP (A-rated, therapeutically equivalent) | June 12, 2014 | 5,000 UNITS/ML |
| FRESENIUS KABI USA LLC | 206552 | AP (A-rated, therapeutically equivalent) | June 10, 2016 | 5,000 UNITS/ML |
| PHARMOBEDIENT CONSULTING LLC | 203851 | AP (A-rated, therapeutically equivalent) | November 30, 2017 | 1,000 UNITS/ML, 10,000 UNITS/ML, 5,000 UNITS/ML |
| EMERGE BIOSCIENCE PTE LTD | 211005 | AP (A-rated, therapeutically equivalent) | December 14, 2018 | 1,000 UNITS/ML |
| EMERGE BIOSCIENCE PTE LTD | 211007 | AP (A-rated, therapeutically equivalent) | May 28, 2019 | 1,000 UNITS/ML, 10,000 UNITS/ML, 5,000 UNITS/ML |
| GLAND PHARMA LTD | 205323 | AP (A-rated, therapeutically equivalent) | November 18, 2019 | 1,000 UNITS/ML, 5,000 UNITS/ML |
| EMERGE BIOSCIENCE PTE LTD | 211004 | AP (A-rated, therapeutically equivalent) | February 24, 2020 | 20,000 UNITS/ML |
| EMERGE BIOSCIENCE PTE LTD | 212060 | AP (A-rated, therapeutically equivalent) | April 2, 2020 | 10,000 UNITS/ML |
| EMERGE BIOSCIENCE PTE LTD | 212061 | AP (A-rated, therapeutically equivalent) | July 15, 2020 | 5,000 UNITS/ML |
| BE PHARMACEUTICALS AG | 214804 | AP (A-rated, therapeutically equivalent) | December 29, 2020 | 1,000 UNITS/ML |
| BE PHARMACEUTICALS AG | 214839 | AP (A-rated, therapeutically equivalent) | December 29, 2020 | 10,000 UNITS/ML |
Questions
Is there a generic for Liquaemin Sodium?
Yes. The generic name for Liquaemin Sodium is heparin. 9 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AP. Generics match 4 of the 5 Liquaemin Sodium products the Orange Book lists.
What is the generic name for Liquaemin Sodium?
The active ingredient in Liquaemin Sodium is heparin, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.